Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Bullboard Posts
Comment by donkeyfeatherson Aug 25, 2014 1:41pm
282 Views
Post# 22875460

RE:RE:RE:RE:RE:RE:SVA SP is Sick

RE:RE:RE:RE:RE:RE:SVA SP is SickCall me crazy (and I know the contributors to this msg string will :), but Shapiro's work is incremental when compared to the overall goal of integrating platform with protectant.  At this stage, if the news is good we might be the beneficiaries of a 30% pop in price (about $.295 per share) if the PR is also good.  That puts the value of the company in the $38 million range, a number in line with a stage of development where "integration effects" have not yet been determined/proven out.  This translates directly into the current risk premium/share price (or the new price floor post announcement).  I've already made clear what I think needs to transpire for a mkt cap of $75 million ($.58 per share).  Of course, bad news out of Edmonton means this all goes back to whatever value can be squeezed out of the exisitng IP.  Thus my insistence on this all still remaining speculative.  Maybe the PR dept.s coagulating of the feces revolves around managing expectations in light of the big picture goals :)
DF
Bullboard Posts